Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence

Completed · Phase 2 · Has a placebo group

Conditions studied: Urinary Bladder, Overactive

In brief

This study will evaluate the safety and efficacy of AGN-214868 in patients with idiopathic overactive bladder (IOAB) and urinary incontinence.

Key facts

Study ID

NCT01157377

Run by

Allergan

People needed

160

Starts

2010-10-01

Expected to finish

2013-05-01

Last updated by the study team

2014-03-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• If female, must be of nonreproductive potential
• If male, must agree to use acceptable contraception
• Symptoms of overactive bladder with urinary urgency incontinence
• Inadequate response or limiting side effects with anticholinergics for the treatment of OAB

You may not qualify if…

• Overactive bladder caused by neurological condition (eg, spinal cord injury, multiple sclerosis)
• History of bladder surgery
• Treatment with botulinum toxin therapy of any serotype for any non-urological condition within the prior 12 weeks
• Previous treatment with botulinum toxin therapy of any serotype for any urological condition

Where it is running

• Study site — Richmond, Virginia, United States
• Study site — Lyon, France
• Study site — Amsterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.